AI assistant
CAMBIUM BIO LIMITED Earnings Release 2017
64666_rns_2017-08-21_b3bc906d-3b23-4325-8a97-ca2c7e36d91f.pdf
Earnings Release
Open in viewerOpens in your device viewer
22nd August 2017
ASX Ltd Level 4, 20 Bridge Street Sydney NSW 2000
Regeneus Ltd (ASX:RGS) - Results for the year ended 30 June 2017
Attached for immediate release to the market are the following documents:
- Regeneus Ltd Appendix 4E Preliminary final report for the year ended 30 June 2017; and
- Regeneus Ltd Annual Report for the year ended 30 June 2017
Yours faithfully
John Martin Director
Appendix 4E
Preliminary financial report for the year ended 30 June 2017
Reporting Period
Report for the full year to 30 June 2017. Corresponding period is for the full year ended 30 June 2016.
| Results for announcement to the market | |||
|---|---|---|---|
| Current | Change | Change | |
| S'000 | S'000 | Z. | |
| Revenue from ordinary activities | 10.069 | 8.191 | 436% |
| Profit from ordinary activities after income tax attributable to members | 3.271 | 6.844 | 192% |
| Net profit for the year attributable to members | 3.271 | 6.844 | 192% |
| 2016 | 2015 | |
|---|---|---|
| Cents | Cents | |
| Basic earnings per share | 0.016 | (0.017) |
| Diluted earnings per share | 0.016 | (0.017) |
| Net tangible asset backing per ordinary share | 3.87 | 2.29 |
Dividends
No dividends are being proposed or have been paid in the current year (2016: Nil).
Audited Annual Accounts
This report is based on the consolidated financial statements that have been audited by Grant Thornton Audit Pty Ltd, with the Independent Auditor's Report included in the financial statements.
The remainder of the information requiring disclosure to comply with listing rule 4.3A is contained in the Operating and Financial Review section of the June 2017 Directors' Report and the audited June 2017 Financial Report, within the Regeneus Ltd Annual Report 2017, lodged with this Appendix 4E.